WO2017193900A1 - Poria cocos skin extract, poricoic acid a, and poricoic acid b and application thereof for blood sugar modulation - Google Patents

Abstract

An application using at least a poricoic acid A and a poricoic acid B for preparing a pharmaceutical product or foodstuff, wherein the pharmaceutical product or foodstuff is used for blood sugar modulation. At least one of the poricoic acid A and poricoic acid B can be used in the form of a plant extract. A total content of the poricoic acid A and poricoic acid B in the plant extract is at least 30% of the total weight of the plant extract. The foodstuff can be used as a health food, dietary supplement food, or specialized nutritional food.

Description

Use of suede extract, ruthenium acid A, and ruthenium acid B to regulate blood sugar Technical field

The present invention relates to the application of ecdysis extract, poricoic acid A, and poricoic acid B, and more particularly to the use of these substances for regulating blood sugar.

Background technique

Diabetes is a chronic metabolic disorder, and its main cause is that the mechanism of glucose uptake by cells in the body is abnormal, causing excessive glucose in the blood. In general, insulin secreted by the beta cells of the pancreas stimulates the uptake of glucose by fat cells and muscle cells, and has the effect of regulating blood sugar. When an organism suffers from insufficient insulin secretion or poor sensitivity to insulin due to factors such as obesity and aging, the blood glucose concentration will increase. Hyperglycemia may cause complications such as high blood pressure, heart disease, arteriosclerosis, and hyperlipidemia. In severe cases, sequelae such as blindness, impotence, amputation, and dialysis may occur.

At present, the clinical treatment of diabetes mainly includes exercise, diet control, and drug treatment, among which drug treatment includes insulin injection, oral hypoglycemic drugs, such as sulfonyl ureas (sufonylureas), biguanides (biguanides), Alpha-glucosidase inhibitors, insulin sensitizers, and the like. However, with the change in human life patterns, the prevalence of diabetes has increased year by year. According to the prediction of the World Health Organization in 2008, it is estimated that the global diabetes population will exceed 300 million people by 2030. Therefore, the industry is still committed to developing drugs or methods with low side effects and effective blood sugar lowering.

The inventors of the present invention have found that the extract of the molting and the poricoic acid A and poricoic acid B contained therein can effectively increase the ability of cells to take up glucose, so it can be used for Regulates blood sugar, especially to provide excellent blood sugar lowering.

Summary of the invention

It is an object of the present invention to provide a use of at least one of ruthenium acid A and ruthenium acid B for the manufacture of a medicament or food, wherein the medicament or food is for regulating blood sugar. The medicine or food is used in an amount of about 0.05 mg/kg body weight to 1 mg/kg body weight per day based on the total weight of the brand new acid A and the brand new acid B, and the food may be a health food, a nutritional supplement or a special nutrition. food.

Preferably, at least one of ruthenium acid A and ruthenium acid B is used in the form of a plant extract. In the plant extract, the total content of the ruthenium acid A and the ruthenium acid B is not less than 30% by weight, preferably not less than 40% by weight based on the total weight of the plant extract. More preferably, at least one of ruthenium acid A and ruthenium acid B is used in the form of a koji extract. In the mink extract, pachymic acid, dehydropachymic acid, tumulosic acid, and dehydromethane are used as the total weight of the molting extract. Dehydrotumulosic acid) is not more than 0.5% by weight, and dehydrotrametenolic acid, trametenolic acid, dehydroeburicoic acid, and eburicoic acid Each content of the product does not exceed 5%. Preferably, in the suede extract, the content of dehydrocarotic acid, ceric acid, dehydroporosic acid, and porphyrin is not based on the total weight of the molting extract. More than 2.5%. More preferably, in the suede extract, the content of dehydrocarotic acid, ceric acid, dehydroporosic acid, and porphyrin is not based on the total weight of the molting extract. More than 1%.

Another object of the present invention is to provide a method of modulating blood glucose in a body comprising administering to an individual in need thereof an effective amount of at least one of ruthenium acid A and ruthenium acid B.

It is still another object of the present invention to provide a blood sugar regulating composition which is a pharmaceutical or food product and which comprises an effective amount of at least one of ruthenium acid A and ruthenium acid B.

Preferably, the suede extract is provided by an operation comprising the following steps:

(a) extracting a rind portion with a first solvent to obtain a crude extract;

(b) drying the crude extract to obtain a crude extract powder;

(c) extracting the crude extract powder with a second solvent to obtain a suede extract,

Wherein the first solvent is the same as or different from the second solvent and is respectively selected from the group consisting of water, ethanol, an alkali solution, an acid solution, and a combination thereof.

Wherein, the first solvent and the second solvent are aqueous ethanol solutions having the same or different ethanol concentration.

The beneficial effects of the present invention are: the extract of the suede of the present invention, and the new acid A and the new acid B can enhance the ability of the living body to take blood sugar, can be used to regulate blood sugar, and in particular can lower the excessive blood sugar. .

DRAWINGS

The present invention will be further described in detail below in conjunction with the drawings and specific embodiments.

Figure 1 shows the results of the glucose oxidase assay, the effect of the extract of the molting on the ability of mouse muscle cells to take up glucose in the culture medium;

Figure 2 shows the results of the glucose oxidase assay, the effect of the extract of the molting on the ability of mouse adipocytes to take up the glucose in the culture medium;

Figure 3A shows the effect of ruthenium acid A on the ability of mouse muscle cells to take up glucose in culture medium by glucose oxidase assay;

Figure 3B shows the effect of ruthenium acid B on the ability of mouse muscle cells to take up glucose in culture medium by glucose oxidase assay;

Figure 4A shows the results of the effect of ruthenium acid A on the ability of mouse adipocytes to take up glucose in culture medium by glucose oxidase assay;

Fig. 4B shows the results of the effect of ruthenium acid B on the ability of mouse adipocytes to take up glucose in culture medium by glucose oxidase method.

detailed description

The invention will be described in detail below. The invention may be practiced in various different forms without departing from the spirit and scope of the invention. In addition, the terms "a", "the", and <RTI ID=0.0> </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; When administered to an individual, the amount of the compound that effectively increases the ability of the individual's cells to take up glucose; the so-called "individual" refers to a mammal, and the mammal can be a human or a non-human animal; the so-called "regulating blood sugar" refers to a normal value. Change the concentration of glucose in the blood; the unit "mg / kg body weight" refers to the amount of drug required per kilogram of body weight.

The range of values used in the specification (for example, 5 to 100) is understood to include all rational numbers in the range and any range of rational numbers in the range, and therefore, the numerical range used in the specification includes All possible combinations of values between the lowest and highest values listed. In addition, when "about" is used herein before the numerical value, it is substantially within 20%, preferably within 10%, and more preferably within 5%.

As explained above, the main cause of diabetes is that the mechanism of glucose uptake by cells in the living body is abnormal, and the glucose content in the blood is too high. The inventors of the present application have found that both ruthenium acid A and ruthenium acid B can increase the ability of cells to take up glucose, so they can be used to regulate blood sugar, especially to reduce excessive blood sugar. Accordingly, the present invention provides at least the use of ruthenium acid A and ruthenium acid B An application for regulating blood sugar, comprising using at least one of ruthenium acid A and ruthenium acid B to prepare a blood sugar regulating drug or food, and administering at least one of ruthenium acid A and ruthenium acid B to an individual in need thereof A method of regulating blood sugar, and providing a food or pharmaceutical composition comprising at least one of ruthenium acid A and ruthenium acid B.

The medicinal material refers to the dried sclerotium of the fungus fungus (Poria cocos (Schw.) Wolf). The fungus is often parasitic on the roots of pine trees. The outer skin is light brown or dark brown (skin), and the interior is pink or white (clam meat). Traditional Chinese medicine records indicate that the clam meat department has calming, diuretic, nutritional supplements, immunity enhancement and delayed aging, while the molting is only used to treat skin edema.

As shown in the appended examples, according to the present invention, a total content of a new acid A and a sensate B can be obtained from the suede portion of not less than 30% by weight (based on the total weight of the molting extract). Extract. Thus, at least one of the neomycin A and the ruthenium B used in accordance with the invention may be used, for example, in the form of a plant extract of a hull extract, wherein the plant extract used in accordance with the invention is planted The total content of the ruthenium acid A and the ruthenium acid B is not less than 30% by weight, preferably not less than 40% by weight, based on the total weight of the extract.

According to the present invention, the suede extract used may be an extract provided by the operation comprising the steps of: (a) extracting the suede portion with a first polar solvent to obtain a crude extract; Drying the crude extract to obtain a crude extract powder; (c) extracting the crude extract powder with a second polar solvent to obtain a suede extract, wherein the first polar solvent and the second The polar solvents are the same or different and are each selected from the group consisting of water, ethanol, lye, acid, and combinations of the foregoing. The lye refers to any suitable alkaline solution having a pH greater than 7 (for example, a sodium hydroxide solution), and the acid solution refers to any suitable acidic solution having a pH of less than 7 (for example, a hydrochloric acid solution). In some embodiments of the invention, An aqueous ethanol solution having the same or different ethanol concentration is used as the first polar solvent and the second polar solvent.

In the step (a), the ratio of the amount of the first polar solvent to the suede portion can be adjusted as needed. In general, the amount of the first polar solvent to be used is not particularly limited as long as the raw materials can be uniformly dispersed. For example, the volume ratio of the first polar solvent to the suede portion may be employed in step (a) from about 8:1 to about 16:1. In one embodiment of the invention, the extraction of step (a) is carried out using an aqueous solution of ethanol as the first polar solvent and a solution of ecdy:ethanol in a volume ratio of about 1:8.

In step (a), a suitable extraction time can be selected depending on the first polar solvent employed. In the case where an aqueous ethanol solution is used as the first polar solvent and the volume ratio of the rind:ethanol aqueous solution is 1:8, the extraction is usually carried out for at least 1 hour, preferably at least 2 hours, more preferably at least 3 hours. Further, other operations such as boiling, cooling, filtration, concentration under reduced pressure, resin column chromatography, and the like may be additionally performed to carry out the step (a). Alternatively, it may be necessary to pre-soak the suede in the first polar solvent for a period of time prior to performing step (a). For example, using an aqueous solution of ethanol as the first polar solvent, pre-soaking can be performed for about 12 hours.

In the step (c), the ratio of the amount of the second polar solvent to the crude extract powder obtained in the step (b) may be adjusted as needed. In general, the amount of the second polar solvent to be used is not particularly limited as long as the coarse extract powder can be uniformly dispersed. For example, the volume ratio of the second polar solvent to the crotch crude extract powder may be employed in step (c) from about 8:1 to about 16:1. In a specific embodiment of the present invention, the extraction of the step (c) is carried out using an aqueous solution of ethanol as the second polar solvent and a crude extract of the molting portion of the mash: an aqueous solution of ethanol in a volume ratio of about 1:8.

The rind extract used in accordance with the present invention may also be a dried product which may be provided by drying the extract obtained in step (c). In order to achieve maximum extraction benefits, Optionally, the extract may be repeatedly extracted with the same or different first polar solvent prior to performing step (b), and the extract obtained by the multiple extractions may be combined to provide a coarse step (b). The extract; the cycle of step (b), step (c), and other operations as desired may also be repeated.

In the suede extract used according to the present invention, the total content of the ruthenium acid A and the ruthenium acid B is not less than 30% by weight, preferably not less than 40% by weight based on the total weight of the ecdy extract. And the content of decanoic acid, dehydroabietic acid, temoic acid, and dehydromomoic acid are not more than 0.5%, dehydrochazymic acid, tradulinic acid, dehydrogenated acid, and porphyric acid Each content does not exceed 5%. Preferably, in the suede extract, the content of dehydrocarotic acid, ceric acid, dehydroporosic acid, and porphyrin is not based on the total weight of the molting extract. More than 2.5%. More preferably, in the suede extract, the content of dehydrocarotic acid, ceric acid, dehydroporosic acid, and porphyrin is not based on the total weight of the molting extract. More than 1%.

The pharmaceutical composition or medicament provided in the application according to the present invention may be in any suitable form, without particular limitation, and may be in a corresponding suitable dosage form depending on the intended use. By way of example, but not by way of limitation, the pharmaceutical composition or medicament may be administered orally or non-orally (eg, subcutaneous, intravenous, intramuscular, or intraperitoneal) to an individual in need thereof. Wherein, depending on the form of use and use, a suitable carrier may be used to provide the pharmaceutical composition or medicament, wherein the carrier comprises an excipient, a diluent, an adjuvant, a stabilizer, an absorption delaying agent, a disintegrating agent. , solubilizers, emulsifiers, antioxidants, binders, binders, tackifiers, dispersants, suspending agents, lubricants, moisture absorbers, etc.

Taking a dosage form suitable for oral administration as an example, the pharmaceutical composition or medicament provided in the application according to the present invention may contain any active ingredient which does not adversely affect the active ingredient (ie, ruthenium A, ruthenium B, or ruthenium) A pharmaceutically acceptable carrier of the desired benefit of the ecdysis extract, for example: water, saline, dextrose, glycerol, ethanol or the like, cellulose, starch, sugar bentonite And combinations of the foregoing. The pharmaceutical composition or medicament may be provided in a dosage form suitable for oral administration by any suitable method, for example, a tablet (for example, a dragee), a pill, a capsule, a granule, a powder, a flow extract, a solution, Syrups, suspensions, tinctures, etc.

As for injections or drips suitable for subcutaneous, intravenous, intramuscular, or intraperitoneal injection, one or more, for example, isotonic solutions, salt buffers may be included in the pharmaceutical compositions or medicaments provided in accordance with the use of the present invention. Liquid (such as phosphate buffer or citrate buffer), solubilizer, emulsifier, 5% sugar solution, and other carriers, such as intravenous infusion, emulsion intravenous infusion, dry powder injection, suspension The pharmaceutical composition or drug is provided in the form of an injection, or a dry powder suspension injection. Alternatively, the pharmaceutical composition or medicament can be prepared as a pre-injection solid, the pre-injection solid is provided in a dosage form or emulsifiable form which is soluble in other solutions or suspensions, and is administered to a desired one. Prior to the individual, the pre-injection solid is dissolved in other solutions or suspensions or emulsified to provide the desired injectable preparation.

Optionally, a pharmaceutical composition or a medicament provided in accordance with the application of the present invention may additionally contain an appropriate amount of an additive, for example, a flavoring agent which enhances the mouthfeel and visual sensation of the pharmaceutical composition or drug when administered, A toner, a coloring agent, and the like, and a buffering agent, a preservative, a preservative, an antibacterial agent, an antifungal agent, and the like which can improve the stability and storage property of the drug. In addition, the pharmaceutical composition or medicament may optionally contain one or more other active ingredients (eg, an antioxidant, an insulin sensitizer, etc.) or may be used in combination with a drug containing the one or more other active ingredients. Further enhancing the efficacy of the pharmaceutical composition or drug or increasing the flexibility and formulation of the formulation of the formulation, as long as the other active ingredient is active on the active ingredient of the present invention (ie, erythroic acid A, bismuth B, or quercetin) The benefits of the extracts are not adversely affected.

The pharmaceutical composition or medicament provided in the application according to the present invention may be administered at different administration times, such as once a day, multiple times a day, or several times a day, depending on the needs, age, weight, and health condition of the individual being administered. Different. For example, when administered orally to an individual to modulate blood glucose, the total amount of ruthenium acid A and ruthenium acid B is from about 0.01 mg/kg body weight to 5 mg/kg body weight per day. Preferably, it is from about 0.03 mg/kg body weight to 2 mg/kg body weight per day, more preferably from about 0.05 mg/kg body weight to 1 mg/kg body weight per day. Alternatively, in an amount of from about 0.025 mg/kg body weight to 25 mg/kg body weight per day, preferably from about 0.075 mg/kg body weight to 10 mg/kg body weight per day, more preferably about 0.125 per day. From mg/kg to 5 mg/kg.

The food provided by the application according to the present invention may be a health food, a nutritional supplement or a special nutritious food, and may be made into, for example, dairy products, processed meats, breads, noodles, biscuits, buns, capsules, juices. Products such as tea, sports drinks, nutritional drinks, etc., but not limited to this. Preferably, the food product for use according to the invention is provided in the form of a health food.

The health food, nutritional supplement food and special nutritious food provided by the application according to the present invention can be eaten at different frequencies once a day, once a day, or several times a day, depending on the age, weight, and health of the individual. The recommended intake for the situation varies. The content of the new acid A, the brand new acid B, or the skin extract of the health food, the nutritional supplement food and the special nutritious food provided by the invention may also be adjusted for a specific ethnic group, preferably adjusted to be taken daily. The amount. For example, based on the total weight of ruthenium acid A and ruthenium acid B, if the recommended intake of an individual is about 70 mg of ruthenium acid A and ruthenium acid B per day, the health food Each serving contains a total of 35 mg of ruthenium A and ruthenium B, and the individual can consume about two servings of the health food per day. Product.

The recommended dosage, the use criteria and conditions of a specific ethnic group (such as pregnant women, diabetic patients, kidney patients), or common foods or medicines may be indicated in the outer packaging of the health food, nutritional supplement food and/or special nutritious food of the present invention. The recommended recommendations are for the user to take it at home without the guidance of a physician, pharmacist or related staff without any security concerns.

The invention also provides a method of modulating blood glucose comprising administering to an individual in need thereof an effective amount of an active ingredient, wherein the active ingredient is at least one of ruthenium acid A and ruthenium acid B. In the method of regulating blood glucose according to the present invention, the aspect of the active ingredient, the administration route, the administration form, the applicable dose, and the application of the related treatment are as described above.

The invention will now be further illustrated by the following examples. The embodiments are provided by way of illustration only and are not intended to limit the scope of the invention. The scope of the invention is as indicated in the claims.

Example

[Preparation Example]

A. Preparation of mink extract

A-1. Take the medicinal herbs (source origin is Yunnan), peel off the outer skin after washing (hereinafter referred to as "skin"), and the rest is the meat department (hereinafter referred to as "the meat department"). The above-mentioned suede portion was taken and immersed in a 75% ethanol aqueous solution at a volume ratio of 1:8 (a medicinal material: aqueous ethanol solution) at room temperature for 12 hours, then boiled and extracted (for 3 hours). The aforementioned extraction steps were repeated for a total of three times. The resulting extract was combined three times and filtered to remove insolubles to obtain a crude extract. Next, the crude extract described above was concentrated under reduced pressure to remove the solvent, and then dried by a spray dryer to obtain a crude extract powder.

A-2. Take the crude extract powder obtained by A-1 at 1:8 (crude extract powder: ethanol aqueous solution) The volume ratio was mixed with 95% ethanol and extracted (for 3 hours), followed by separation using a column packed with silica gel as a stationary phase to obtain a suede extract.

A-3. The crude extract powder obtained in A-1 was uniformly dispersed in pure water in a volume ratio of 1:10 (crude extract powder: water). Next, sodium hydroxide was added to raise the pH of the mixture to about 12, and then poured into a brewing tank maintained at a temperature of 65 ° C and uniformly stirred until the reaction was completed. Then, it was neutralized with 12 N concentrated hydrochloric acid, and the filtrate was removed by centrifugation, and the remaining insoluble matter was washed with pure water, and the insoluble matter was dried by a spray dryer to obtain an extract powder. The above extract powder was extracted three times with a 1 N aqueous solution of sodium hydrogencarbonate in a volume ratio of 1:20 (extract powder: 1 N aqueous sodium hydrogencarbonate), and the extract obtained by three times extraction was carried out with 12 N concentrated hydrochloric acid. And, after centrifugation, the filtrate was removed, and the remaining insoluble matter was washed with pure water, and the insoluble matter was dried by a spray dryer to obtain a suede extract.

A-4. The components of the extract obtained by A-2 and A-3 were detected by liquid chromatography/ultraviolet/mass spectrometry at 243 nm and 210 nm respectively, and subjected to high performance liquid chromatography. The content of each component in each of the extracts was quantified, and the analysis results of the extracts obtained from A-2 are shown in Table 2, and the results of the analysis of the extracts obtained in Tables 1 and A-3 are shown in Table 2.

Table 1

ingredient	weight%
Pachymic acid (PA)	-
Dehydropachymic acid (DPA)	-
Tumulosic acid (TA)	-
Dehydrotumulosic acid (DTA)	0.46
Polyporenic acid C (PAC)	2.01
3-epi-dehydrotumulosic acid (EDTA)	0.77

Dehydrotrametenolic acid (DTTA)	2.01
Trametenolic acid (TTA)	0.85
Icoico acid A (PAA)	32.72
Dehydroeburicoic acid (DEA)	1.20
Poric acid B (PAB)	10.44
Eburicoic acid (EA)	0.83

Table 2

ingredient	weight%
Pachymic acid (PA)	-
Dehydropachymic acid (DPA)	-
Tumulosic acid (TA)	-
Dehydrotumulosic acid (DTA)	0.31
Polyporenic acid C (PAC)	1.15
3-epi-dehydrotumulosic acid (EDTA)	0.40
Dehydrotrametenolic acid (DTTA)	0.58
Trametenolic acid (TTA)	0.35
Icoico acid A (PAA)	41.06
Dehydroeburicoic acid (DEA)	0.19
Poric acid B (PAB)	16.50
Eburicoic acid (EA)	0.20

As can be seen from Table 1, the mink extract obtained by A-2 contains a high amount of ruthenium acid A (32.72% by weight of the extract) and ruthenium B (the weight percentage of the extract is 10.44). %), low amounts of dehydroabietic acid, ceric acid, dehydroporosporin and streptococcus (2.01%, 0.85%, 1.2%, 0.83% by weight of the extract, respectively), and Very low amount of dehydrogenation Tallow acid (0.46% by weight of the extract), but does not contain tannic acid, dehydroabietic acid and toluic acid.

As can be seen from Table 2, the molting extract obtained by A-3 contains a high amount of ruthenium acid A (41.06% by weight of the extract) and ruthenium acid B (16.50% by weight of the extract). ), low amount of porcine acid C, dehydroabietic acid (1.15%, 0.58% by weight of extract), and very low amount of dehydrohydro acid, 3-epoxy-dehydromethane Acid, ceric acid, dehydroporosporin and porphyric acid (0.31%, 0.40%, 0.35%, 0.19%, 0.20% by weight of the extract, respectively), but without decanoic acid, dehydrogenation Tannic acid and tomic acid.

B. Preparation of ruthenium acid A and ruthenium acid B

B-1. The molting extract obtained by A-2 or A-3 was uniformly dissolved in methanol at a volume ratio of 1:500 (skin extract: methanol). After insoluble matter was removed by filtration, a preparative high-performance liquid chromatograph (mixed with methanol and water as a mobile phase) was used to separate and collect the neomycin A and the ruthenium B at a wavelength of 243 nm. After that, the methanol was removed by a vacuum condenser to obtain ruthenium acid A and ruthenium acid B, respectively.

B-2. The new acid A and the ruthenium acid B obtained by B-1 were detected by liquid chromatography/ultraviolet/mass spectrometry at 243 nm, respectively, and the results showed that ruthenium acid A and ruthenium acid were obtained. The purity of B is greater than 98%.

C. Cell culture

Differentiated mouse muscle cells (C2C12, purchased from ATCC) and adipocytes (3T3-L1, purchased from ATCC) were cultured in Duss containing 2% bovine serum albumin (BSA) but not serum-free. The medium was modified in Dulbecco's modified Eagle's medium (DMEM) for 16 hours. Next, using Dulbecco's phosphate-buffered Saline, D-PBS) was washed and the medium was changed to 0.2% BSA-DMEM medium containing 500 μg/ml glucose for subsequent experiments.

Example 1: Effect of extract of ecdysone on the ability of cells to take up glucose

(1-1) Muscle cells

The C2C12 cells provided in [Preparation Example] were taken, divided into five groups and cultured in the following medium for 2 hours:

1. Group I: BSA-DMEM medium containing 500 μg glucose/ml;

2. Group II: BSA-DMEM medium containing 500 micrograms of glucose per milliliter and insulin at a concentration of 100 nanomolar;

3. Group III: BSA-DMEM medium containing 500 μg of glucose/ml, and a solution of the ecdysis extract provided in [Preparation Example A-2] at a concentration of 0.1 μg/ml;

4. Group IV: BSA-DMEM medium containing 500 μg of glucose/ml, and a solution of the ecdysis extract provided in [Preparation Example A-2] at a concentration of 1 μg/ml;

5. Group V: BSA-DMEM medium containing 500 μg of glucose/ml, and a solution of the molting extract provided in [Preparation Example A-2] at a concentration of 10 μg/ml.

Thereafter, the glucose content in each group of cell culture fluids was measured by the glucose oxidase method to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose). Finally, the relative glucose uptake ability of the other groups was calculated based on the results of the control group (i.e., the cells cultured in the first group culture solution), and the results are shown in Fig. 1.

As can be seen from Fig. 1, the glucose uptake capacity of cells treated with the extract of the molting portion of the present invention (i.e., cells cultured in the culture medium of Group III, IV, or V) is significantly improved, even beyond the positive control group, compared to the control group. Control group (ie, cells cultured in Group II culture). The above results show that this issue Alum extract can effectively increase the ability of muscle cells to take up glucose, so it can be used to regulate blood sugar.

(1-2) fat cells

The 3T3-L1 cells provided in [Preparation Example] were taken, divided into five groups and cultured in the medium groups I to V described in Example 1 (1-1) for 2 hours. Next, the glucose content in each group of cell culture fluids was measured by the glucose oxidase method to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose). Finally, the relative glucose uptake ability of the other groups was calculated based on the results of the control group (i.e., the cells cultured in the first group culture solution), and the results are shown in Fig. 2.

As can be seen from Fig. 2, the glucose uptake ability of the cells treated with the extract of the molting portion of the present invention (i.e., cells cultured in the culture medium of Group III, IV, or V) has an increasing tendency compared to the control group. Among them, the upward trend of the high dose group (cells cultured in the group V culture medium) was the most significant. The foregoing results show that the extract of the suede of the present invention can effectively enhance the ability of fat cells to take up glucose, and thus can be used to regulate blood sugar.

Example 2: Effect of ruthenium acid A and ruthenium acid B on glucose uptake by cells

(2-1) Muscle cells

The C2C12 cells provided in [Preparation Example] were taken, divided into eight groups and cultured in the following medium for 2 hours:

1. Group i: BSA-DMEM medium containing 500 μg glucose/ml;

2. Group ii: BSA-DMEM medium containing 500 micrograms of glucose per milliliter and insulin at a concentration of 100 nanomolar;

3. Group iii: contains 500 micrograms of glucose per milliliter, and a concentration of 0.1 micrograms per milliliter BSA-DMEM medium of ruthenic acid A or ruthenic acid B provided in [Preparation Example B-1];

4. Group iv: BSA-DMEM medium containing 500 μg glucose/ml, and a concentration of 1 μg/ml of the ruthenium acid A (or ruthenium acid B) provided in [Preparation Example B-1];

5. Group v: BSA-DMEM medium containing 500 μg/ml of glucose and ruthenic acid A (or ruthenium B) provided in [Preparation Example B-1] at a concentration of 10 μg/ml.

Next, the glucose oxidase method was used to determine the glucose content in each group of cell culture fluids to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose), and finally, to control the group (ie, to culture in the i-th culture medium) The relative glucose uptake ability of the other groups was calculated based on the results of the cells, and the results are shown in Fig. 3A and Fig. 3B. Wherein, FIG. 3A includes a control group, a positive control group (ie, cells cultured in the ii group culture medium), and a group treated with ruthenium acid A (ie, cultured in the iii, iv, or v group) The result of the cell, wherein the culture solution contains the ruthenium acid A). 3B includes a control group, a positive control group, and a group treated with ruthenium acid B (ie, cells cultured in the culture medium of group iii, iv, or v, wherein the culture solution contains ruthenium B) result.

As can be seen from Fig. 3A, the glucose uptake capacity of the group treated with ruthenium acid A was significantly increased to be comparable to that of the positive control group as compared with the control group. The foregoing results show that ruthenium acid A can effectively increase the ability of muscle cells to take up glucose, so it can be used to regulate blood sugar.

As can be seen from Fig. 3B, the glucose uptake ability of the group treated with ruthenium acid B was also significantly improved as compared with the control group. The foregoing results show that ruthenium B can also regulate blood sugar by increasing the ability of muscle cells to take up glucose.

(2-2) fat cells

Take the 3T3-L1 cells provided in [Preparation Example], divide them into eight groups and respectively use Example 2 (ii) The ith to v-group culture medium was cultured for 2 hours. Next, the glucose content in each group of cell culture fluids was measured by the glucose oxidase method to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose). Finally, the relative glucose uptake ability of the other groups was calculated based on the results of the control group (i.e., the cells cultured in the i-th culture medium), and the results are shown in Fig. 4A and Fig. 4B. 4A includes a control group, a positive control group (ie, cells cultured in the ii group culture medium), and a group treated with ruthenium acid A (ie, cultured in the iii, iv, or v group) The result of the cell, wherein the culture solution contains the ruthenium acid A). 4B includes a control group, a positive control group, and a group treated with ruthenium acid B (ie, cells cultured in the culture medium of group iii, iv, or v, wherein the culture solution contains ruthenium B) result.

As can be seen from Fig. 4A, the glucose uptake ability of the group treated with ruthenium acid A has an increasing tendency compared with the control group, wherein the middle dose group (i.e., the cells cultured in the iv group) and the high The upward trend of the dose group (i.e., the cells cultured in the vth culture medium) was significant. The foregoing results show that ruthenium acid A can effectively increase the ability of fat cells to take up glucose, so it can be used to regulate blood sugar.

As can be seen from Fig. 4B, the glucose uptake ability of the group treated with ruthenium acid B was significantly improved as compared with the control group. The foregoing results show that ruthenium B can also regulate blood sugar by increasing the ability of fat cells to take up glucose.

As shown in the above examples, the extract of the suede of the present invention, and the ruthenium acid A and the ruthenium acid B can enhance the ability of the living body to take up blood sugar, can be used to regulate blood sugar, and in particular can reduce excessive blood sugar. .

Claims (13)

1. A use of at least one of poricoic acid A and poricoic acid B for the manufacture of a medicament or food, characterized in that the medicament or food is used for regulating blood sugar.
2. The use according to claim 1, characterized in that at least one of ruthenium A and ruthenium B is used in the form of a plant extract.
3. The use according to claim 2, characterized in that the total content of ruthenium acid A and ruthenium acid B is not less than 30% by weight based on the total weight of the plant extract.
4. The use according to claim 3, characterized in that the total content of ruthenium acid A and ruthenium acid B is not less than 40% by weight based on the total weight of the plant extract.
5. The use according to any one of claims 2 to 4, characterized in that the plant extract is a molting extract.
6. The use according to claim 5, characterized in that pachymic acid, dehydropachymic acid, tumulosic acid, and The content of dehydrotumulosic acid is not more than 0.5%.
7. The use according to claim 5, characterized in that dehydrotrametenolic acid, trametenolic acid, dehydroeburiic acid (dehydroeburicoic), based on the total weight of the molting extract The acid content and the content of eburicoic acid are not more than 5%.
8. The use according to claim 7, wherein the content of dehydrocarotic acid, ceric acid, dehydroporosic acid, and porphyrin is not based on the total weight of the rind extract. More than 2.5%.
9. The use according to claim 8 wherein the total weight of the extract of the suede portion The content of dehydrochaetidic acid, thiocyanate, dehydroporosporin, and porphyric acid is not more than 1%.
10. The use according to claim 5, wherein the suede extract is provided by an operation comprising the following steps:

    (a) extracting a rind portion with a first solvent to obtain a crude extract;

    (b) drying the crude extract to obtain a crude extract powder;

    (c) extracting the crude extract powder with a second solvent to obtain a suede extract,

    Wherein the first solvent is the same as or different from the second solvent and is respectively selected from the group consisting of water, ethanol, an alkali solution, an acid solution, and a combination thereof.
11. The use according to claim 10, wherein the first solvent and the second solvent are aqueous ethanol solutions having the same or different ethanol concentrations.
12. The use according to claim 1, wherein the medicament or food is used in an amount of from about 0.05 mg/kg body weight to 1 mg/kg body weight per day based on the total weight of the ruthenium acid A and the ruthenium acid B.
13. The use according to claim 1, wherein the food is a health food, a nutritional supplement or a special nutritious food.

Images